Pharmacological characterization of AC-90179 [2-(4-methoxy-phenyl)-N-(4- methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: A selective serotonin 2A receptor inverse agonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 3, 2004, Pages 943-951

  Vanover, Kimberly E ^a   Harvey, Scott C ^a   Son, Thomas ^a   Bradley, Stefania Risso ^a   Kold, Henriette ^a   Makhay, Malath ^a   Veinbergs, Isaac ^a   Spalding, Tracy A ^a   Weiner, David M ^a   Andersson, Carl Magnus ^a   Tolf, Bo Ragnar ^a   Brann, Mark R ^a   Hacksell, Uli ^a   Davis, Robert E ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 METHOXYPHENYL) N (4 METHYLBENZYL) N (1 METHYLPIPERIDIN 4 YL)ACETAMIDE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AC 90179; ACETAMIDE DERIVATIVE; CLOZAPINE; HALOPERIDOL; PHENCYCLIDINE; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; HUMAN; INSTRUMENTAL CONDITIONING; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

3T3 CELLS; ANIMALS; BENZAMIDES; BIOLOGICAL AVAILABILITY; BRAIN; CACO-2 CELLS; CATALEPSY; CELL MEMBRANE PERMEABILITY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; MOTOR ACTIVITY; NOSE; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS;

EID: 4243182599     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.066688     Document Type: Article

References (32)

1. Barnes TR and McPhillips MA (1998) Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 13 (Suppl 3):S49-S57.
2. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, and Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122.
3. Canton H, Verriele L, and Millan MJ (1994) Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett 181:65-68.
4. Carlsson A, Waters N, and Carlsson ML (1999a) Neurotransmitter interactions in schizophrenia: therapeutic implications. Biol Psychiatry 15:1388-1395.
5. Carlsson ML, Martin P, Nilsson M, Sorensen SM, Carlsson A, Waters S, and Waters N (1999b) The 5-HT2A receptor antagonist M100907 is more effective in counter-acting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. J Neural Transm 106:123-129.
6. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, and Dunn RW (1995) Antipsychatic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74.
7. Crocker AD and Hemsley KM (2001) An animal model of extrapyramidal side effects induced by antipsychatic drugs: relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 25:573-590.
8. Freed WJ, Bing LA, and Wyatt RJ (1984) Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropsychopharmacology 23:175-181.
9. Gleason SD and Shannon HE (1997) Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84.
10. Goldstone S, Nurnberg HG, and Lhamon WT (1979) Effects of trifluoperazine, chlorpromazine and haloperidol upon temporal information processing by schizophrenic patients. Psychopharmacology 65:119-124.
11. Herrick-Davis K, Grinde E, and Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 295:226-232.
12. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133.
13. Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, and Quiner S (1999) Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. Eur Arch Psychiatry Clin Neuro Sci 249:83-89.
14. Kurz M, Hummer M, Oberbauer H, and Fleischhacker WW (1995) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118:52-56.
15. Maurel-Remy S, Bervoets K, and Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280: R9-R11.
16. McGurk SR and Meltzer HY (2000) The role of cognition in vocational functioning in schizophrenia. Schizophr Res 27:175-184.
17. Meltzer HY, Matsubara S, and Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246.
18. Meltzer HY and McGurk SR (1999) The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
19. Meltzer HY, Park S, and Kessler R (1999) Cognition, schizophrenia and the atypical autipsychotic drugs. Proc Nat Acad Sci USA 96:13591-13593.
20. Millan MJ, Brocco M, Gobert A, Bervoets JF, Rivet J, Newman-Tancredi A, Audinot V, and Maurel S (1999) Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11:4419-4432.
21. Ninan I and Kulkarni SK (1998) 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur J Pharmacol 358:111-116.
22. Ninan I and Kulkarni SK (1999) Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur J Pharmacol 368:1-7.
23. O'Neill MF and Shaw G (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology 145:237-250.
24. Rauser L, Savage JE, Meltzer HY, and Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83-89.
25. Snyder S (1976) The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 133:197-202.
26. Vanover KE (1997) Effects of AMPA receptor positive modulators on amphetamine- and dizocilpine-induced locomotion. Eur J Pharmacol 332:115-119.
27. Vanover KE and Barrett JE (1998) An automated learning and memory model in mice: pharmacological and behavioral evaluation of an autoshaped response. Behav Pharmacol 9:273-283.
28. Velligan DI and Miller AL (1999) Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 80:25-28.
29. Wainscott DB, Lucaites VL, Kursar JD, Baez M, and Nelson DL (1996) Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther 276:720-727.
30. 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299:268-276.
31. Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, Hocherman S, and Davidson M (2000) Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS? Schizophr Res 46:81-89.
32. Worrel JA, Marken PA, Beckman SE, and Ruehter VL (2000) Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 57:238-255.